The combination of sotigalimab (APX005M) and nivolumab (Opdivo) elicited durable responses with a reasonable safety profile in patients with melanoma who were refractory to anti–PD-1 therapy, according to data from a phase 2 trial (NCT03123783).
Archive | Clinical Trials
Sotigalimab Plus Nivolumab Shows Encouraging Activity in Anti–PD-1 Refractory Melanoma
Posted in Melanoma News, Health Professionals, Clinical Trials
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC– Enrollment Stopped Early for Efficacy
EXTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) –Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Idera’s synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early.
Posted in Melanoma News, Health Professionals, Clinical Trials
Nivolumab + Relatlimab Continues Clinical Benefit in Advanced Melanoma
The combination of nivolumab and relatlimab continues to demonstrate a progression-free survival (PFS) benefit compared to nivolumab alone in patients with previously untreated metastatic or unresectable melanoma. In addition, for the first time, the dual checkpoint inhibitor therapy also demonstrated a higher overall response rate (ORR), according to follow-up data from the RELATIVITY-047 trial.
Posted in Melanoma News, Health Professionals, Clinical Trials
Combo of BO-112 and Pembrolizumab Elicits Response in Advanced Melanoma
In patients with advanced melanoma who were resistant to anti–PD-1 therapies, adding BO-112 to pembrolizumab (Keytruda) demonstrated efficacy and safety, according to final results from the phase 2 SPOTLIGHT203 trial (NCT04570332).
Posted in Melanoma News, Health Professionals, Clinical Trials
 |
 |
 |
 |
